Stock Track | Tango Therapeutics Plunges 7.11% in Pre-Market as Q4 Results Show No Revenue, Widened Loss

Stock Track03-05

Tango Therapeutics Inc. (TNGX) experienced a pre-market plunge of 7.11% following the release of its fourth-quarter financial results.

The biotechnology firm reported a net loss of $38.7 million for the quarter, compared to a loss of $30.8 million a year earlier. Notably, the company recorded no collaboration revenue for the period, a significant drop from the $5.4 million generated in the same quarter of the previous year. While the loss per share narrowed to $0.29 from $0.32, the widening absolute net loss and absence of revenue likely contributed to negative investor sentiment.

Despite the disappointing quarterly figures, the company highlighted a robust cash position of $343.1 million, which it expects to fund operations into 2028. Tango also announced a new clinical collaboration with Erasca to evaluate its PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015, though this positive development was overshadowed by the earnings miss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199169497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199169497","market":"nz","top_or_hot":-1,"title":"Stock Track | Tango Therapeutics Plunges 7.11% in Pre-Market as Q4 Results Show No Revenue, Widened Loss","media":"Stock Track","content":"<p>Tango Therapeutics Inc. (TNGX) experienced a pre-market plunge of 7.11% following the release of its fourth-quarter financial results.</p><p>The biotechnology firm reported a net loss of $38.7 million for the quarter, compared to a loss of $30.8 million a year earlier. Notably, the company recorded no collaboration revenue for the period, a significant drop from the $5.4 million generated in the same quarter of the previous year. While the loss per share narrowed to $0.29 from $0.32, the widening absolute net loss and absence of revenue likely contributed to negative investor sentiment.</p><p>Despite the disappointing quarterly figures, the company highlighted a robust cash position of $343.1 million, which it expects to fund operations into 2028. Tango also announced a new clinical collaboration with Erasca to evaluate its PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015, though this positive development was overshadowed by the earnings miss.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tango Therapeutics Plunges 7.11% in Pre-Market as Q4 Results Show No Revenue, Widened Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tango Therapeutics Plunges 7.11% in Pre-Market as Q4 Results Show No Revenue, Widened Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tango Therapeutics Inc. (TNGX) experienced a pre-market plunge of 7.11% following the release of its fourth-quarter financial results.</p><p>The biotechnology firm reported a net loss of $38.7 million for the quarter, compared to a loss of $30.8 million a year earlier. Notably, the company recorded no collaboration revenue for the period, a significant drop from the $5.4 million generated in the same quarter of the previous year. While the loss per share narrowed to $0.29 from $0.32, the widening absolute net loss and absence of revenue likely contributed to negative investor sentiment.</p><p>Despite the disappointing quarterly figures, the company highlighted a robust cash position of $343.1 million, which it expects to fund operations into 2028. Tango also announced a new clinical collaboration with Erasca to evaluate its PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015, though this positive development was overshadowed by the earnings miss.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1199169497","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199169497","pubTimestamp":1772715776,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tango Therapeutics Inc. (TNGX) experienced a pre-market plunge of 7.11% following the release of its fourth-quarter financial results.The biotechnology firm reported a net loss of $38.7 million for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc."},"translate_title":"个股追踪|Tango Therapeutics盘前暴跌7.11%因Q4业绩显示无营收亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1},"content_text":"Tango Therapeutics Inc. (TNGX) experienced a pre-market plunge of 7.11% following the release of its fourth-quarter financial results.The biotechnology firm reported a net loss of $38.7 million for the quarter, compared to a loss of $30.8 million a year earlier. Notably, the company recorded no collaboration revenue for the period, a significant drop from the $5.4 million generated in the same quarter of the previous year. While the loss per share narrowed to $0.29 from $0.32, the widening absolute net loss and absence of revenue likely contributed to negative investor sentiment.Despite the disappointing quarterly figures, the company highlighted a robust cash position of $343.1 million, which it expects to fund operations into 2028. Tango also announced a new clinical collaboration with Erasca to evaluate its PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015, though this positive development was overshadowed by the earnings miss.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199169497","isCrawlerRequest":true}